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Abstract
Background: Leptospirosis is an infectious disease caused by the spirochete of the genus leptospira. It is thought to be the most common zoonosis globally and 
has a wide range of clinical presentations with pulmonary hemorrhage being one of its most severe manifestations. This entity known as acute pulmonary syn-
drome carries a high fatality rate. However, it can be effectively managed with methylprednisolone therapy. Case: We report a case of leptospirosis in a 26-year-old 
Bangladeshi male who was otherwise healthy. He presented with a 7-day history of fever with chills and rigors, and hemoptysis for a duration of 2 days. Physical 
examination revealed a febrile and lethargic man. Respiratory examination exhibited bilateral generalized crepitations over the lung fields. A chest radiograph 
performed showed bilateral alveolar shadowing. The diagnosis of leptospirosis was made based on positive Immunoglobulin M enzyme-linked immunosorbent 
assay serology, which was then confirmed by the microscopic agglutination test for leptospirosis.  The patient was commenced on intravenous antibiotics and 
methylprednisolone at this time. He responded well clinically with resolution of fever and hemoptysis and a marked decrease in crepitations upon auscultation. 
This correlated with radiological improvement evidence by an obvious reduction in alveolar shadowing on subsequent chest radiograph 2 days later. Conclusion: 
This case is highly pertinent to the medical field as leptospirosis is an ever-growing problem and acute pulmonary syndrome is an emerging manifestation of 
it. Therefore, early recognition and intervention is required as this can be effectively treated with methylprednisolone therapy even in resource-limited settings.
Keywords: Fever; Hemoptysis; Leptospirosis; Methylprednisolone; Agglutination Tests (Source: MeSH, NLM).
About the Author: Iman 
Daniel is currently a fi-
nal-year medical student 
at Monash University 
Malaysia. He has a keen 
interest in pathology and 
was offered the Pathology 
Update 2015 Conference 
scholarship to attend the 
conference in Melbourne, 
Australia.
Introduction
Leptospirosis is a very common zoonotic infection, with a geo-
graphically ubiquitous distribution worldwide. It is caused by a 
thin and coiled spirochete under the genus of leptospira and 21 
species of leptospira have been identified, 13 of which are con-
sidered pathogenic.1 Leptospirosis is an emerging infectious ill-
ness, with higher incidences in warm, humid, tropical countries. 
Leptospiral acute pulmonary syndrome (APS) is an increasingly 
prevalent clinical entity that brings serious complications with 
a very high mortality rate. It is the most common cause of dea-
th in cases of leptospirosis.2 Symptoms include progressive he-
moptysis and dyspnea which ultimately leads to patients dying 
from asphyxiation and respiratory failure.2 Thus, it is important 
to make a prompt diagnosis and initiate early treatment with 
the appropriate therapy. The microscopic agglutination test 
(MAT) is widely used in the confirmation of the diagnosis of 
leptospirosis. 
Despite the notorious pulmonary manifestations of the disea-
se, methylprednisolone therapy is highly effective in reducing 
morbidity and mortality rates. It is proposed that treatment 
within 12 hours of recognition of pulmonary involvement in 
leptospirosis can be lifesaving.3 In addition, methylpredniso-
lone therapy also reduces the need for ventilator support and 
therefore, makes it a feasible choice when it comes to a hospi-
tal setting with limited resources.3 This case is unique, as there 
have only been a handful of similar cases within the literature 
which describes the efficacy of methylprednisolone in treating 
leptospiral acute pulmonary syndrome.
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          Key Points:
• Pulmonary hemorrhage is an emerging manifestation of leptospirosis, 
with a high fatality rate if early intervention is not initiated.
• The pathophysiology of pulmonary hemorrhage in leptospirosis oc-
curs via an immune mediated pathway, with deposition of immunoglo-
bulins and complement on the pneumocytes, thus making immunosu-
ppressant and anti-inflammatory agents an excellent choice of therapy.
• Early intervention with high dose methylprednisolone for the first 3 
days followed by oral prednisolone is effective in reducing the severity 
of leptospiral acute pulmonary syndrome.
• Methylprednisolone therapy reduces the needs for tertiary referral 
and critical care, thus enabling patients to be treated in a district set-
ting without further deterioration.
The Case
A 26-year-old male of Bangladeshi nationality, who was pre-
viously healthy, developed persistent fever of one-week dura-
tion. He presented to a district hospital in the state of Johor, 
Malaysia, with a high-grade fever that was associated with 
chills, rigors and body aches. On day 3 of the fever, he ex-
perienced a dry cough and shortness of breath, which then 
progressed to massive hemoptysis on day 5. He denied any 
night sweats, rashes or lethargy. Systems review for cardiovas-
cular, gastrointestinal, neurological and genitourinary systems 
were unremarkable. Past medical history and family history 
were not significant. He has no known allergies. There was no 
tuberculosis contact. He abstains from alcohol and denied any 
illicit drug use. He is a chronic smoker of 5 pack-years. He is 
married and has been working in Malaysia for a year. Currently, 
he is working in an oil palm plantation where his job involved 
constant contact with soil. He claimed to have gone swimming 
in a waterfall a week prior to the onset of fever. 
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Examination revealed a dehydrated patient with cool extremi-
ties. He had subconjunctival suffusion which is characterized 
by conjunctival redness especially on the palpebral conjunc-
tiva.  There was no obvious skin rash. Vital signs recorded a 
blood pressure of 101/82 mmHg. He was tachycardic at 118 
beats per minute with a reduced radial pulse volume.  His 
temperature was 38.2o C and he had an oxygen saturation of 
90% on room air. He was also jaundiced with an associated 
pallor. No cervical lymph nodes were palpable. Respiratory exa-
mination revealed bilateral generalized crepitations over the 
lung fields. Cardiovascular, abdominal and neurological exami-
nations were unremarkable. 
The complete blood count showed a mild anemia of 10.6 g/
dL, leukocytosis (13.9 x 109/L) with predominant neutrophi-
lia (absolute neutrophil count of 12.1 x 109/L) and significant 
thrombocytopenia (48 x 109/L). His coagulation profile showed 
prolonged prothrombin time of 16.3 seconds and a normal acti-
vated partial thromboplastin time and international normalized 
ratio (INR). His renal profile showed urea of 7.1 mmol/L, high 
serum creatinine (197 umol/L), hypokalemia (3.09 mmol/L), 
and a normal sodium level. The liver function tests showed 
deranged liver enzymes. The alanine transaminase (ALT) was 
102 U/L and aspartate aminotransferase (AST) was 143 U/L. The 
alkaline phosphatase (ALP) was 158 U/L, albumin of 34 g/L and 
total bilirubin of 85.2 umol/L with unconjugated bilirubin pre-
dominating. He also had an elevated C-reactive protein level 
of 15.8 mg/L and erythrocyte sedimentation rate of 97 mm/hr. 
Arterial blood gas exhibited features of type 1 respiratory failu-
re and high anion gap metabolic acidosis with pH of 7.28, pO2 
58 mmHg, normal pCO2 and bicarbonate of 17 mmol/L. Urine 
examination was normal. Chest radiograph revealed bilateral 
alveolar shadowing as shown in Figure 1. 12-lead electrocardio-
gram and the 2-D transthoracic echocardiogram were normal. 
Urine, sputum and blood samples for culture returned with no 
growth and no acid-fast bacilli were detected in the sputum 
samples. Blood film for malarial parasites did not reveal any 
evidence of parasitemia and serology for dengue was negati-
ve. Leptospirosis IgM ELISA was positive. A high titer of 1:400 
microscopic agglutination test confirmed the diagnosis of lep-
tospirosis. 
With regards to this patient’s management, he was started on 
intravenous tranexamic acid (500 mg) three times daily to stop 
the hemorrhage. He was immediately commenced on intra-
venous benzyl penicillin at a dose of 1200 mg every 6 hours, 
which was maintained for 1 week. He was also given intrave-
nous methylprednisolone 15 mg/kg daily for 3 days. 
He responded well clinically to the treatment as shown by 
a marked reduction in hemoptysis. Pulmonary auscultation 
showed decreased crepitations bilaterally. Chest radiograph 
revealed a significant reduction in alveolar opacities on day 2 
post-treatment as shown in Figure 2. He was discharged home 
on a tapering dose of oral prednisolone at 40 mg for the first 2 
days, 30 mg for the subsequent 2 days and 20 mg for the last 2 
days. At follow-up one month later, he was symptom free and 
in good health. An informed written consent was obtained from 
the patient prior to the writing of this case report.
Johan Arief ID, et al. Methylprednisolone-Responsive Leptospiral Acute Pulmonary Syndrome: A Case Report
Figure 1. A posterior-anterior (PA) view of the patient’s chest 
radiograph on admission showing gross alveolar shadowing, 
suggestive of intra-alveolar hemorrhage.
Figure 2. Patient’s repeat chest X-ray (PA view) 2 days after 
IV methylprednisolone therapy, showing marked reduction in 
airspace nodular opacities and infiltration.
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Discussion
Leptospirosis is an infectious illness, which is recently increa-
sing in incidence. It is a medical problem with an annual in-
cidence rate ranging from 10 to 100 cases per 100000 people 
annually in the tropical areas. Leptospirosis is usually trans-
mitted through direct and indirect contact with animal urine. 
The incubation period for leptospirosis ranges from 2 to 30 
days.1 The presentation of this disease can be broadly clas-
sified into the following 4 groups: a mild viral flu-like illness, 
Weil’s disease (acute kidney injury with hepatitis-like picture), 
meningitis or meningoencephalitis, and pulmonary hemorr-
hage with subsequent respiratory insufficiency. (World Health 
Organization. Available from: http://www.paho.org/hq/index.
php?option=com_content&view=article&id=7821%3Ainforma-
cion-general-leptospirosis-&catid=4711%3Aleptospirosis-ho-
me&Itemid=40695&lang=en, updated 2015 January 15; cited 
2015 Jul 11).
The gold standard investigation is the microscopic agglutination 
test (MAT), which involves the mixing of the patients’ antibo-
dies with live leptospira antigens.4 An agglutinate or a clump 
formation shows a positive reaction, which can then be viewed 
under dark field microscopy.4 One of the major drawbacks of 
this test is that it is highly dependent on the production of 
antibodies in the host. Thus, during the acute phase of the 
disease where the circulating leptospires have not evoked a full 
immune response, the antibody levels would be minimal and 
would subsequently lead to a false negative result.5
Leptospiral APS is manifested by profuse intra-alveolar hemorr-
hage with symptoms such as dyspnea, cough and hemoptysis 
developing on the 4th to 6th day of illness.2 This aggressive 
form of the disease has a fatality rate of 74% despite intensive 
and critical therapy being provided.6 
The pathophysiology of leptospiral APS appears to be immu-
ne-mediated.4 The proposed mechanism begins with the activa-
tion of the endothelium which leads to an increase in vascular 
permeability which allows immunoglobulins such as IgG, IgM 
and IgA to leak out and deposit on the walls of type I and type 
II pneumocytes.7 The activation and deposition of complement 
C3 then ensues, resulting in cell necrosis and subsequent he-
morrhage into the alveolar spaces resulting in a histopatholo-
gical pattern that is not seen with other forms of pulmonary 
hemorrhage.7 Leptospiral toxins also activate tumor necrosis 
factor alpha (TNF-α), which is an acute phase reactant produ-
ced primarily by macrophages.8  Local effects of TNF-α triggers 
the cardinal signs of inflammation with systemic effects being 
fever and leukocytosis. 
Multiple nodular densities which represent alveolar hemorrhage 
can be appreciated on the chest radiograph. These may progress 
to form a confluent consolidation that subsequently resolves, lea-
ving an indistinct ground-glass pattern that is diffuse in nature.9
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There are various corticosteroid therapies available in the rural 
setting such as hydrocortisone, dexamethasone, methylpred-
nisolone and oral prednisolone. Intravenous hydrocortisone 
plays a huge role in acute exacerbations of asthma and chronic 
obstructive pulmonary disease (COPD). Oral prednisolone the-
rapy is given as a short course following these exacerbations 
and also as a maintenance therapy for certain chronic cases. 
Intravenous dexamethasone on the other hand is indicated in 
cases of raised intracranial pressure. Intravenous methylpred-
nisolone has been effectively used in cases of cerebral lupus 
and lupus nephritis. However, its availability in the rural setting 
is limited. Also, methylprednisolone with its high anti-inflam-
matory and immunosuppressive properties plays an important 
role in decreasing the severity of leptospiral APS.8 Pharmaco-
logic doses of glucocorticoid-based therapy can reverse the 
effect of immune-mediated response and therefore, lessen 
the disease-associated vasculitis by reducing the cytokine and 
TNF-α production.8 
In a study by Shenoy et al., 61.53% of patients showed signifi-
cant improvement when treated with intravenous methylpred-
nisolone 1g daily for 3 days during the early course (within the 
first 12 hours) of pulmonary leptospirosis.3 It is also beneficial 
in severe cases where mortality was seen to decrease from 
85.71% to 33.33%.3 The study also demonstrated a reduced 
need for ventilator support with methylprednisolone therapy. 
This data is useful for rural hospitals with limited resources. 
In another study by Kularatne et al., it was observed that a 
regime of intravenous methylprednisolone 500mg for 3 days 
followed by oral methylprednisolone 8mg for 5 days played 
a significant role in reducing mortality rates due to pulmo-
nary involvement specifically.10 This study also showed that 
the development of multiple organ dysfunction as the disease 
progressed can hinder the efficacy of methylprednisolone the-
rapy.10 This is crucial since a delay in the hospitalization of 
patients with leptospiral APS in tropical areas due to an initial 
misdiagnosis of dengue fever has led to a poorer outcome of 
these patients.2 
In conclusion, leptospiral APS carries a high mortality rate and 
is an emerging manifestation of leptospirosis. The success of 
intravenous methylprednisolone therapy as described in this 
case report shows that APS can be managed effectively in a 
district setting without any need for tertiary care in certain 
circumstances.
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